Stem’s main risk is sequencing, not product existence. It must preserve liquidity, convert
backlog and
ARR into real cash, and defend
PowerTrack’s neutral workflow role against
OEM bundling before creditors, refinancing terms, or
dilution absorb the upside that would otherwise accrue to common holders.